| Authors: |
Lipson EJ; The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, The Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA. Electronic address: evanlipson@jhmi.edu., Stephen Hodi F; Dana-Farber Cancer Institute, Boston, MA, USA., Tawbi H; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Schadendorf D; University of Essen and the German Cancer Consortium, Essen, Germany., Ascierto PA; Istituto Nazionale dei Tumori IRCCS 'Fondazione G. Pascale', Naples, Italy., Matamala L; Instituto Oncológico Fundación Arturo López Pérez and Department of Oncology, Instituto Nacional del Cáncer, Santiago, Chile., Gutierrez EC; FAICIC Clinical Research, Veracruz, Mexico., Rutkowski P; Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland., Gogas HJ; National and Kapodistrian University of Athens, Athens, Greece., Lao CD; Michigan Medicine, Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA., Menezes JJ; Hospital Nossa Senhora da Conceição, Porto Alegre, Brazil., Dalle S; Hospices Civils de Lyon, Cancer Research Center of Lyon, Pierre-Bénite, France., Arance A; Hospital Clinic Barcelona and IDIBAPS, Barcelona, Spain., Gaudy-Marqueste C; Aix-Marseille University, APHM, CHU Timone, Marseille, France., Chen B; Bristol Myers Squibb, Princeton, NJ, USA., Jackson W; Bristol Myers Squibb, Princeton, NJ, USA., Mukherjee S; Bristol Myers Squibb, Princeton, NJ, USA., Dolfi S; Bristol Myers Squibb, Princeton, NJ, USA., Long GV; Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, NSW, Australia. |
